Advertisement
UK markets close in 5 hours 41 minutes
  • FTSE 100

    8,082.26
    +37.45 (+0.47%)
     
  • FTSE 250

    19,790.44
    -9.28 (-0.05%)
     
  • AIM

    754.45
    -0.42 (-0.06%)
     
  • GBP/EUR

    1.1629
    +0.0001 (+0.01%)
     
  • GBP/USD

    1.2431
    -0.0022 (-0.17%)
     
  • Bitcoin GBP

    53,347.14
    +122.63 (+0.23%)
     
  • CMC Crypto 200

    1,433.57
    +9.47 (+0.66%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    82.91
    -0.45 (-0.54%)
     
  • GOLD FUTURES

    2,327.10
    -15.00 (-0.64%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,196.72
    +59.07 (+0.33%)
     
  • CAC 40

    8,126.73
    +20.95 (+0.26%)
     

Shire surge pushes FTSE towards record peak

* FTSE 100 up 0.3 percent

* Shire (LSE: SHP.L - news) jumps after rejecting bid valuing it at $46 bln

* TSB shares up about 14 pct on London stock market debut

By Tricia Wright

LONDON, June 20 (Reuters) - British drugmaker Shire (Dusseldorf: S7E.DU - news) surged on Friday after rebuffing a takeover offer and helped prop up the FTSE 100, which traders bet will inch further towards its record high in coming days.

Shire jumped 13.1 percent to a record high after rejecting a bid from AbbVie Inc (NYSE: ABBV - news) which would have valued the group at around 27 billion pounds ($46 billion), the U.S. firm said.

ADVERTISEMENT

"In my opinion, the move higher in early trade confirms the growth potential for Shire is huge: as such I could see the stock stretching to at least 50 pounds," Jordan Hiscott, senior trader at ayondo markets, said. That would hoist the stock some 18 percent above current levels.

With its tax base in Ireland (Other OTC: IRLD - news) , where effective corporate tax rates are among the lowest in the world, Shire, with a mid-sized market value, has been seen as a prime takeover target for U.S. drugmakers.

Panmure Gordon, which described Shire's rare diseases business as "one of the hottest assets in biopharmaceuticals", said it was no surprise to see Abbvie's approach rejected, with the broker calling its offer "barely adequate".

"Abbvie may be able to increase its offer to more than 50 pounds, which we believe will be required to make this deal happen", the broker said, but added that would depend on circumstances regarding the possible benefits of tax inversion.

Panmure increased its price target for Shire to 4,626 pence - in line with AbbVie's latest offer - and re-iterated its "buy" recommendation on the stock.

Shire accounted for half of the FTSE 100's 18.69 point gain, or 0.3 percent, to 6,826.80 by 0757 GMT. The index rose 0.4 percent on Thursday after the U.S. Federal Reserve reassured investors on monetary policy.

Traders remained bullish on the index, which is sitting within reach of a record high 6,950.60 set in 1999.

"I think the FTSE is a buy at these levels," said Mark Ward, Sanlam Securities' head of trading, who expected the FTSE to hit 6,900 in the coming days.

In an otherwise quiet day, shares in TSB Banking Group Plc were trading at 296.1 pence in early trading following its stock market debut, up nearly 14 percent on the 260 pence price set for its initial public offering. ($1 = 0.5864 British pounds) (Reporting by Tricia Wright; Editing by Susan Fenton)